All In Biotech

Drug Trial Radar · NCT05736731

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530, an Autologous Logic-gated Tmod™ Chimeric Antigen Receptor T Cell (CAR T), in Heterozygous HLA-A*02 Adult Subjects With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Last checked: Nov 20, 2026Latest source record: Apr 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Apr 28, 2023

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
A2 Biotherapeutics Inc.Industry
Sponsor type
Industry
Collaborators
Tempus AI
First posted
Feb 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that express CEA and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the maximum or recommended dose of A2B530 that is safe for patients * Phase 2: Does the recommended dose of A2B530 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: * Enrollment and Apheresis in BASECAMP-1 (NCT04981119) * Preconditioning Lymphodepletion (PCLD) Regimen * A2B530 Tmod CAR T cells at the assigned dose

Conditions

  • Solid Tumor, Adult
  • Solid Tumor
  • Pancreatic Cancer
  • Pancreatic Neoplasms
  • Pancreas Cancer
  • Non Small Cell Lung Cancer
  • Non Small Cell Lung Cancer Recurrent
  • Non-Small Cell Squamous Lung Cancer
  • NSCLC
  • NSCLC, Recurrent
  • Colorectal Cancer
  • Colorectal Neoplasms
  • Colorectal Adenocarcinoma
  • CRC
  • Colorectal Cancer Metastatic
  • Cancer

Interventions

  • A2B530Biological

    Autologous logic-gated Tmod CAR T-cells

  • xT-Onco with HLA-LOH AssayDiagnostic test

    An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose levelTime frame: From the time of Informed consent until 24 months (2 years) post A2B530 infusion.
  2. Phase 1: Recommended Phase 2 Dose (RP2D)Time frame: 21 days post A2B530 infusion
  3. Phase 2: The Overall Response Rate (ORR) for patientsTime frame: 24 months post A2B530 infusion

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Banner Health

    Gilbert, Arizona

  • University of California San Diego

    La Jolla, California

  • UCLA Medical Center

    Los Angeles, California

  • Moffitt Cancer Center

    Tampa, Florida

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Washington University

    St Louis, Missouri

  • NYU Langone Medical Center

    New York, New York

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.